InDevR Appoints Chief Commercial Officer

InDevR, an analytical technology, life science instrumentation and medical device company, has appointed Dawn Bitz as vice president, chief commercial officer, effective immediately.

Prior to joining InDevR, Bitz was a successful entrepreneur and executive holding more than $500 million in global P&L (profit and loss) responsibilities.
 
 “Dawn is a tremendous leader who will build a world-class commercial team at InDevR,” said Dr. Kathy Rowlen, CEO. “Her experience in growing world-class businesses, planning and executing commercial strategies and overseeing multiple launches will play a critical role in InDevR’s next phase of growth.”
 
During her more than 20-year career, Bitz has been a corporate executive, entrepreneur and consultant. She has held prominent positions with multi-billion-dollar medical device and pharmaceutical companies, consulted for small and mid-cap companies, led mergers and integrations of $250 million acquisitions, and has held more than $500 million in P&L responsibilities globally. Early in her career she worked clinically on the ambulance and in the hospital, managing both pharmaceutical and medical device research studies. She translated that foundation into a business management and commercial career. Bitz has led global marketing, sales, product development, business development and commercial operations for companies like Covidien plc, Boston Scientific Corp. and UCB Pharma. She also founded and sold a consumer product goods and technology company.

Bitz will lead InDevR’s commercial efforts, including product sales, marketing, business development and licensing, communications, public relations and investor relations.
 
Bitz holds undergraduate degrees in biology and chemistry from Texas Christian University and is a registered nurse and paramedic.
 
“I am excited to join InDevR at a time when we have the opportunity to shape commercial strategies for new and innovative ways to streamline and expedite the commercial vaccine production process. I look forward to building and leading a top-tier organization that will impact our ability to fight influenza and other public health issues,” she said.
 
Based in Boulder, Colo., InDevR provides progressive analytical technologies that enhance and accelerate vaccine characterization and production. The company also develops next-generation diagnostic products that will enable unprecedented tracking of seasonal and emerging influenza viruses around the globe.